Last reviewed · How we verify
pristinamycin
pristinamycin is a drug. It is currently in unknown development.
At a glance
| Generic name | pristinamycin |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Approved indications
Common side effects
Key clinical trials
- A Phase III, Open, Randomised, Multicentre Study Comparing the Efficacy and Safety of Pristinamycin, at Dosages of 50 mg/kg/d in 2 Doses for Children, and 1g Twice Daily in Adults for 4 Days Versus Am (Phase 3)
- A Multi-centre, Non-inferiority, Randomized, Double-blind, Phase IV Study Comparing Pristinamycin (2g x 2 Per Day for 2 Days Then 1g x 3 Per Day for 5 to 7 Days) to Amoxicillin (1g x 3 Per Day) for 7 (Phase 4)
- Pristinamycin in the Treatment of MSSA Bone and Joint Infection (N/A)
- Three Weeks Versus Six Weeks Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis : a Multicenter, Randomized, Open-label and Controlled Study (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- pristinamycin CI brief — competitive landscape report
- pristinamycin updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about pristinamycin
What is pristinamycin?
pristinamycin is a pharmaceutical drug.
What development phase is pristinamycin in?
pristinamycin is in unknown.
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing